OPY Acquisition Corp. I is a blank check company formed in 2020 and headquartered in New York, New York. The company primarily operates as a special purpose acquisition company (SPAC) with the objective of effecting a merger, capital stock exchange, asset acquisition, stock purchase, or reorganization with one or more businesses. It does not have significant operations or commercial products of its own. OPY Acquisition Corp. I mainly targets companies in the life sciences industry, including novel therapeutics, medical devices, and related services that enhance patient outcomes. The company completed an upsized initial public offering in 2021 raising approximately $110 million.
A major recent development is the company's announcement in late 2023 of its intent to liquidate after determination that it would be unable to consummate a business combination by the extended deadline, with its public shares scheduled for cancellation by the end of December 2023. This liquidation decision followed careful consideration of market conditions and the inability to secure a suitable value-creating transaction. Consequently, the company is proceeding with dissolution and anticipates delisting from NASDAQ. There have been no new product launches, acquisitions, or strategic partnerships announced in the last 1-2 years due to the company’s SPAC liquidation process. OPY Acquisition Corp. I functions solely as a blank check vehicle with no ongoing operations post-liquidation announcement.